1
|
Gamboa-Aguilar J, Zamorano-Montaño ÁC, Enríquez-Osorio A, Torres-Cubillas W, López-Arroyo JL, Chapol JAM, Zurita-Martínez H, Pascual JR, Saldaña-Campos E, Rojas-Castillejos F, Madera-Maldonado CE, Peñafiel COR, Maldonado EB, Rascón RG, Hernández-Juárez J, Silos-Briones G, Domínguez SDLM, Pérez-Ramírez ÓDJ, Sosa-Camas RE, Romero-López C, Guzmán-Chores L, Amador-Sánchez R, Ledesma-de la Cruz C, Campos-Cabrera G, Ramírez-Chávez LL, Esparza-García JC, Vela-Ojeda J, García-Chávez J, González-Trejo JJ, Rodríguez-Mejorada SM, Rosado-Castro RA, de Arredondo RASM, Pérez-Hernández VH, Majluf-Cruz K, Domínguez-Reyes V, Arreola-Diaz R, Alvarado-Moreno JA, Majluf-Cruz A. Abo Blood Group, Atherothrombotic Comorbidities, and COVID-19: A Case-Control Study of their Association in the Mexican Population. Arch Med Res 2021; 53:100-108. [PMID: 34649737 PMCID: PMC8504860 DOI: 10.1016/j.arcmed.2021.09.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 08/25/2021] [Accepted: 09/23/2021] [Indexed: 01/10/2023]
Abstract
Background COVID-19 has been associated with negative results in patients with A blood group and with a better evolution in O blood group individuals. Aim Because the evidence regarding ABO blood groups and COVID was empirically not that clear in our country, we tested the association regarding COVID-19 and blood groups. Material and Methods Adult patients were enrolled in this prospective, case-control, observational multicenter study. Patients with a confirmed diagnosis of COVID-19 were assigned to one of three groups based on the clinical presentation of the infection. Age, gender, ABO and Rh blood groups, body mass index, history of diabetes mellitus or high blood pressure, and smoking were recorded directly or from their clinical charts. ABO blood group was obtained from 5,000 blood donors (50% each gender). Atherothrombotic variables were compared with a nation-wide data collection. Results A total of 2,416 patients with COVID-19 were included (women:39.6%; men:60.4%). There were no significant differences between cases and controls in terms of age. O blood group was the most frequently found in healthy donors and COVID-19 patients, but this blood group was significantly higher in COVID-19 patients vs. healthy donors. ABO blood group was not associated with the final health status in COVID-19 patients. Obesity, diabetes mellitus, hypertension and smoking were significantly more frequent among COVID-19 patients. Conclusion The proposed protective effect of the O blood group in COVID-19 patients could not be reproduced in the Mexican population while some atherothrombotic risk factors had a significant effect on the clinical evolution.
Collapse
Affiliation(s)
- Jacqueline Gamboa-Aguilar
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Ángela Carele Zamorano-Montaño
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Aldo Enríquez-Osorio
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Wendoline Torres-Cubillas
- Laboratorio Central, Hospital de Especialidades Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Luis López-Arroyo
- Hospital General B, Instituto Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad Juárez, Chihuahua, México
| | | | - Hugo Zurita-Martínez
- Hospital Juan Graham, Secretaría de Salud de Tabasco, Villahermosa, Tabasco, México
| | | | - Eli Saldaña-Campos
- Hospital Juan Graham, Secretaría de Salud de Tabasco, Villahermosa, Tabasco, México
| | - Flavio Rojas-Castillejos
- Servicio de Hematología, Hospital General con Especialidades, Secretaría de Salud, Salina Cruz, Oaxaca, México
| | | | - Christian Omar Ramos Peñafiel
- Servicio de Hematología, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud. Ixtapaluca, Estado de México, México
| | - Emanuel Bermeo Maldonado
- Dirección Quirúrgica, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud, Ixtapaluca, Estado de México, México
| | - Rafael García Rascón
- Servicio de Medicina Interna, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud. Ixtapaluca, Estado de México, México
| | - Jesús Hernández-Juárez
- CONACYT-Facultad de Odontología, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, Oaxaca, México
| | - Graciela Silos-Briones
- Servicio de Hematología, Hospital General de Zona No. 50, Instituto Mexicano del Seguro Social, San Luis Potosí, San Luis Potosí, México
| | | | | | - Rosa Elena Sosa-Camas
- Servicio de Medicina Interna, Hospital General de Hermosillo, Hermosillo, Sonora, México
| | - Cuauhtémoc Romero-López
- Unidad de Terapia Intensiva, Hospital Universitario de Puebla, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, México
| | - Laura Guzmán-Chores
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Raquel Amador-Sánchez
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Cindy Ledesma-de la Cruz
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | - Juan Carlos Esparza-García
- Banco de Sangre, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Jorge Vela-Ojeda
- Departamento de Hematología, Unidad Médica de Alta Especialidad, Hospital Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Jaime García-Chávez
- Departamento de Hematología, Unidad Médica de Alta Especialidad, Hospital Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Joaquín González-Trejo
- Servicio de Medicina Transfusional, Hospital General Dr. Belisario Domínguez, Instituto Seguridad y Servicios Sociales de los Trabajadores del Estado, Tuxtla Gutiérrez, Chiapas, México
| | | | | | | | - Víctor Hugo Pérez-Hernández
- Servicio de Hematología, Hospital General de Zona Nueva Frontera, Instituto Mexicano del Seguro Social, Tapachula, Chiapas, México
| | - Karim Majluf-Cruz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Víctor Domínguez-Reyes
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Rodrigo Arreola-Diaz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Antonio Alvarado-Moreno
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Abraham Majluf-Cruz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México.
| |
Collapse
|
2
|
Xu Y, Siegal DM, Anand SS. Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. J Thromb Haemost 2021; 19:30-40. [PMID: 33078911 DOI: 10.1111/jth.15140] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 10/05/2020] [Accepted: 10/12/2020] [Indexed: 12/21/2022]
Abstract
Despite decades of improvement in its diagnosis and management, venous thromboembolism (VTE) remains a significant cause of cardiovascular morbidity and mortality. Clinically relevant differences exist in the risk of symptomatic VTE among ethnoracial groups. Underlying these differences in rates of VTE are patterns of known genetic thrombophilias, which may also influence the risks of major bleeding related to vitamin K antagonists or direct oral anticoagulants. In addition, social factors, differential access to care, and disease awareness differ between ethnoracial groups, which contributes to disparities in VTE outcomes that include higher fatal events. The vast majority of participants included in clinical trials for the prevention and treatment of VTE have been White Caucasian, which limits our understanding of the differential impact of these agents in non-White ethnoracial groups. Increasing the participation in clinical trials of diverse ethnoracial groups should be a priority, especially those groups who are disproportionately affected by the burden of VTE, or possible bleeding complications when exposed to anticoagulants. Advocacy by patients, researchers, and regulatory bodies is crucial to ensure adequate enrolment of diverse ethnoracial groups in order to best inform clinical decisions to optimize VTE prevention and treatment for non-White populations.
Collapse
Affiliation(s)
- Yan Xu
- Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
| | - Deborah M Siegal
- Hamilton Health Sciences, Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Sonia S Anand
- Hamilton Health Sciences, Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
5
|
Meillón-García LA, Hernández-Zamora E, Montiel-Manzano G, Zavala-Hernández C, Ramírez-San Juan E, Cesarman-Maus G, Reyes-Maldonado E. Anticoagulant proteins in a population of Mexican mestizo donors. Ann Vasc Surg 2014; 29:222-6. [PMID: 25463331 DOI: 10.1016/j.avsg.2014.09.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Revised: 08/11/2014] [Accepted: 09/04/2014] [Indexed: 10/24/2022]
Abstract
BACKGROUND To determine the activity of antithrombin (AT), protein C (PC), and protein S (PS), as well as the frequency of deficiencies of these proteins in a population of healthy Mexican mestizo blood donors. METHODS AT, PC, and PS were determined from 1,502 plasma samples of healthy blood donors by using commercial kits in a coagulometer 4 STA (Diagnostica Stago, Asnières, France). RESULTS A total of 741 women and 761 men were under study. They were divided into age range groups (18-24, 25-34, 35-44, 45-54, and 55-64 years). Activity of AT, PC, and PS was determined. For AT, activity values were specific for each age group according to gender when it had to do with PS, as well as when PC was determined. Frequencies of AT, PC, PS, and activated PC resistance activity deficiencies were obtained from reference levels (RLs) and average levels of this study. Differences were found between both frequencies for AT, PC, and PS, and the average levels obtained were used in this study. The frequencies of the activity deficiencies obtained through the values gotten in this population were: AT, 0.6%; PC, 1.06% (which is higher than the one obtained using the RLs described by commercial kits 0.33% and 0.66%, respectively); and PS, 1% (which is less than 4.5%). CONCLUSIONS It is necessary to know the characteristics and biological behavior of the coagulation proteins in the Mexican population because the RLs used have been established for populations that are genetically different.
Collapse
Affiliation(s)
| | | | | | | | - Eduardo Ramírez-San Juan
- Physiology Department, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico
| | | | - Elba Reyes-Maldonado
- Morphology Department, Cytology Laboratory, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.
| |
Collapse
|
6
|
Arenas-Sordo MDLL, Zavala-Hernández C, Casiano-Rosas C, Reyes-Maldonado E, Ríos C, Hernández-Zamora E, Del Valle-Cabrera MG, Yamamoto-Furusho JK. Leiden V Factor and Spastic Cerebral Palsy in Mexican Children. Genet Test Mol Biomarkers 2012; 16:978-80. [DOI: 10.1089/gtmb.2012.0017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | - Camilo Ríos
- Neurochemical Department, INNN, Mexico City, México
| | | | | | | |
Collapse
|